Antimicrobial activity and stability to beta-lactamase of BMY-28271, a new oral cephalosporin ester.
AUTOR(ES)
Matsui, H
RESUMO
BMY-28271, the acetoxyethyl ester of BMY-28232, 7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3(Z) -propen-1-yl-3- cephem-4-carboxylic acid, is a new oral cephalosporin. BMY-28232 has a widely expanded spectrum with high activity against gram-positive and gram-negative bacteria. BMY-28232 is far more active than cefixime or cefteram against Staphylococcus aureus and Staphylococcus epidermidis. Against gram-negative bacteria, the activity of BMY-28232 was comparable to or somewhat weaker than that of cefixime or cefteram. BMY-28232 was a poor substrate for various beta-lactamases. Orally administered BMY-28271 had a good therapeutic effect on systemic infections with S. aureus and some gram-negative bacteria in mice. Oral BMY-28271 was efficacious against S. aureus Smith infection: the efficacy of BMY-28271 was 80 to 90 times higher than that of cefixime or cefteram.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=171643Documentos Relacionados
- Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.
- Antimicrobial activity and beta-lactamase stability of foramidocillin.
- In vitro antibacterial activity and beta-lactamase stability of E-0702, a new cephalosporin.
- Beta-lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum.
- In vitro activity and beta-lactamase stability of GR69153, a new long-acting cephalosporin.
